← Leaderboards
Allen B Reitz
Als Biopharma, Llc
$1,436,597
Attributed
$2,495,193
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $455.5K · FY2011–24$500K$375K$250K$125K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,495,193 · 2
By mechanism
R01$2,117,193 · 1
R21$378,000 · 1
Top collaborators
- Scott M Rawls5 shared
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsAnimal ModelNervous System DisorderPharmaceutical PreparationsGenerationsDesignIn VivoMetabolicProteinsRattusLinkBaseAddictionBehavioralAgonistAstrocytesClinicClinical TranslationAqueousCerebellar AtaxiaAffectBrainBrain IschemiaAntibiotic Resistance
Grant awards (7)
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$414,677
R01 · FY2024 · DA
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$414,677
R01 · FY2023 · DA
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$414,677
R01 · FY2022 · DA
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$417,646
R01 · FY2021 · DA
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$455,516
R01 · FY2020 · DA
Small Molecule Probes for TAR DNA Binding Protein 43_TDP-43$189,000
R21 · FY2012 · NS · contact PI
Small Molecule Probes for TAR DNA Binding Protein 43_TDP-43$189,000
R21 · FY2011 · NS · contact PI